5-IODO-2'-DEOXYURIDINE-PROTEIN CONJUGATES - SYNTHESIS AND ENZYMATIC DEGRADATION

被引:8
作者
BARANOWSKAKORTYLEWICZ, J [1 ]
ADELSTEIN, SJ [1 ]
KASSIS, AI [1 ]
机构
[1] HARVARD UNIV, SCH MED,SHIELDS WARREN RADIAT LAB,DEPT RADIOL, 50 BINNEY ST, BOSTON, MA 02115 USA
来源
SELECTIVE CANCER THERAPEUTICS | 1990年 / 6卷 / 01期
关键词
D O I
10.1089/sct.1990.6.1
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Several halogenated analogs of thymidine and cytidine possess antineoplastic and antiviral activity. They are also powerful sensitizers of bacterial and mammalian cells to lethal effects of x-irradiation. An important factor limiting the effectiveness of these agents in therapy is their extremely short half-life in circulation due to rapid hepatic dehalogenation. An approach to this problem is to deliver the drug directly to its target using monoclonal antibodies. This study evaluates the lysosomotropic delivery systems of halogenated pyrimidines using 5-iodo-2′-deoxyuridine [IUdR] as a model. IUdR, derivatized and activated at either the 3′- or the 5′-position forms covalent adducts with the ε-amino groups of the lysine residues in proteins (bovine serum albumin [BSA], and immunoglobulins [IgG]). Two methods suitable for conjugation of IUdR to proteins involving either the formation of acyl-imidazoles in the reaction of IUdR succinates with N,N′-carbonyldiimidazole or the preparation of N-succinimidyl esters of IUdR succinates were established. Both derivatives express comparable reactivity toward proteins. The degree of IUdR incorporation is easily controlled by the ratio of reagents. The succinate “arm“ linking IUdR to protein is susceptible to lysosomal hydrolysis in vitro releasing intact IUdR. The half-life of the IUdR-IgG conjugate in the presence of the lysosomal enzymes was shown to be approximately twice that of the IUdR-BSA conjugate. © 1990, Mary Ann Liebert, Inc. All rights reserved.
引用
收藏
页码:1 / 13
页数:13
相关论文
共 48 条
[1]   USE OF ESTERS OF N-HYDROXYSUCCINIMIDE IN PEPTIDE SYNTHESIS [J].
ANDERSON, GW ;
CALLAHAN, FM ;
ZIMMERMAN, JE .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1964, 86 (09) :1839-+
[2]  
BAGSHAWE KD, 1986, LANCET, V2, P778
[3]  
BARANOWSKAKORTY.J, J NUCL MED
[4]  
BARBANTIBRODANO G, 1972, EXPERIENTIA, V30, P1180
[5]   5-I-125-IODODEOXYURIDINE AS PROTOTYPE FOR RADIONUCLIDE THERAPY WITH AUGER EMITTERS [J].
BLOOMER, WD ;
ADELSTEIN, SJ .
NATURE, 1977, 265 (5595) :620-621
[6]  
CALABRES.P, 1965, ANN NY ACAD SCI, V130, P192
[7]   IODINATION OF 2'-DEOXYCYTIDINE AND RELATED SUBSTANCES [J].
CHANG, PK ;
WELCH, AD .
JOURNAL OF MEDICINAL CHEMISTRY, 1963, 6 (04) :428-&
[8]  
CRONKITE EP, 1983, BLOOD CELLS, V9, P107
[9]  
Dische Z, 1944, P SOC EXP BIOL MED, V55, P217
[10]   COVALENT STRUCTURE OF AN ENTIRE GAMMAG IMMUNOGLOBULIN MOLECULE [J].
EDELMAN, GM ;
CUNNINGHAM, BA ;
GALL, WE ;
GOTTLIEB, PD ;
RUTISHAUSER, U ;
WAXDAL, MJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1969, 63 (01) :78-+